A Phase I Dose Escalation With Two Disease Specific Expansions, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of LOR-253 in Patients With Relapsed or Refractory Hematologic Malignancies

Trial Profile

A Phase I Dose Escalation With Two Disease Specific Expansions, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of LOR-253 in Patients With Relapsed or Refractory Hematologic Malignancies

Suspended
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs APTO 253 (Primary)
  • Indications Acute myeloid leukaemia; Haematological malignancies; Lymphoma; Multiple myeloma; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Aptose Biosciences
  • Most Recent Events

    • 08 Aug 2017 According to an Aptose Biosciences media release, the company is planning to submit findings from Preliminary root cause analyses studies to the FDA to reintroduced APTO-253 into the clinical trial.
    • 14 Nov 2016 According to an Aptose Biosciences media release, the company's clinical team has identified and prepared multiple new clinical sites for the Phase 1b trial of APTO-253. The clinical sites, at major cancer research and treatment centers in the U.S., will be prepared to start the study as soon as the company resumes trial activities and re-initiates dosing and enrollment after the approval by FDA to do so.
    • 13 Oct 2016 According to Aptose Biosciences media release, the company has received a response from the U.S. Food and Drug Administration (FDA) regarding the clinical hold of Phase 1b clinical trial of APTO-253 in patients with hematologic cancers requesting additional information and informing Aptose that the hold would not be removed until this information is submitted and reviewed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top